Evidence map›Paper›PMID 15850551›Full record

ReviewThe American journal of medicine2005

Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus.

Richard R Rubin

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in The American journal of medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04841096 (Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure), which is not on this map. Cited by 131 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
131citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04841096 phase3completedstarted 2023, after this paper: background citation

Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure

Ran2023Enrolled162Registered outcomes5Posted comparisons0ConditionsType 2 DiabetesArmsA1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), (A2) Glimepiride/Vildagliptin/Metformin, (B2) Glimepiride/Vildagliptin/Metformin, B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
PMID 9585393PMID 32022600PMID 27088241PMID 24199686PMID 22246944PMID 30072404PMID 28155046PMID 26775266PMID 26519337PMID 31862745PMID 7589820PMID 29405543other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

131 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.Diabetic medicine : a journal of the British Diabetic Association · 2009
    Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Investigating the effect of prescribing status and patient characteristics on the therapeutic outcomes in patients with diabetes using a leftover drug adjustment protocol.Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2024
    Article
  19. Development and calibration data for the Medication Adherence Item Bank: a new computer adaptive test for persons with type 2 diabetes mellitus.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Article
  20. Article

71 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Richard R RubinDepartment of Medicine and Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland 21210, USA. rrubin443@aol.com

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many patients who have type 2 diabetes mellitus (DM) require several different medications. Although these agents can substantially reduce diabetes-related morbidity and mortality, the extent of treatment benefits may be limited by a lack of treatment adherence. Unfortunately, little information is available on treatment adherence in patients with type 2 DM. Available data indicate substantial opportunity for improving clinical outcomes through improved treatment adherence. Factors that appear to influence adherence include the patient's comprehension of the treatment regimen and its benefits, adverse effects, medication costs, and regimen complexity, as well as the patient's emotional well-being. Outcomes research emphasizes the importance of effective patient-provider communication in overcoming some of the barriers to adherence. This article offers specific suggestions for improving adherence in patients with type 2 DM seen in general clinical practice.

Indexed as

Patient ComplianceDepressionDiabetes Mellitus, Type 2Drug CostsHealth Knowledge, Attitudes, PracticeHumansHypoglycemic AgentsPatient Education as TopicPhysician-Patient RelationsStress, PsychologicalHypoglycemic Agents

Identifiers

PMID15850551

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.